Aquestive Therapeutics, Inc.
AQST · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.15 | -0.11 | -0.10 | -0.03 |
| FCF Yield | -2.44% | -8.50% | -2.00% | -2.64% |
| EV / EBITDA | -43.20 | -15.70 | -22.93 | -57.69 |
| Quality | ||||
| ROIC | -15.03% | -22.92% | -16.33% | -8.70% |
| Gross Margin | 54.40% | 58.12% | 61.91% | 67.24% |
| Cash Conversion Ratio | 0.82 | 0.58 | 1.02 | 0.38 |
| Growth | ||||
| Revenue 3-Year CAGR | -3.34% | -1.74% | 5.23% | 6.48% |
| Free Cash Flow Growth | 65.92% | -261.85% | 45.62% | -69.86% |
| Safety | ||||
| Net Debt / EBITDA | -7.20 | 1.87 | 2.64 | 5.74 |
| Interest Coverage | -2.66 | -4.53 | -3.21 | -1.97 |
| Efficiency | ||||
| Inventory Turnover | 0.56 | 0.51 | 0.75 | 0.63 |
| Cash Conversion Cycle | 31.25 | -17.45 | -28.79 | 53.18 |